Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Multiepitope Intranasal Adenoviral Vaccine Induces Robust Mucosal Immunity and Protection against SARS‑CoV‑2.

Journal of nanobiotechnology·2026

Same author

Trained ILCs confer adaptive immunity-independent protection against influenza.

Journal of virology·2025

Same author

Summary of taxonomy changes ratified by the International Committee on Taxonomy of Viruses (ICTV) from the Animal DNA Viruses and Retroviruses Subcommittee, 2025.

The Journal of general virology·2025

Same author

A multi-antigen-based SARS-CoV-2 vaccine provides higher immune responses and protection against SARS-CoV-2 variants.

NPJ vaccines·2025

Same author

A bovine adenoviral-vector-based universal influenza vaccine confers protection against influenza A and B viruses in mice and ferrets.

Molecular therapy. Nucleic acids·2025

Same author

Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2.

Vaccines·2025

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

Bovine Adenoviral Vector-Based Platform for Vaccine Development.

Ekramy E Sayedahmed¹, Vivek Gairola¹, Muralimanohara S T Murala¹

¹Department of Comparative Pathobiology and Purdue Institute of Inflammation, Immunology and Infectious Disease, College of Veterinary Medicine, Purdue University, 625 Harrison St., West Lafayette, IN 47907-2027, USA.

|May 28, 2025

Summary

Bovine adenovirus type 3 (BAdV-3) offers a novel vaccine platform, overcoming preexisting immunity issues associated with human and chimpanzee adenovirus vectors. This system shows promise for next-generation infectious disease vaccines.

Keywords:

bovine adenoviral vector-based platform bovine adenovirus genome organization nonhuman adenoviral vector system pathogenesis virion structure

More Related Videos

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production

Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production

Published on: May 3, 2024

Related Experiment Videos

Last Updated: Jun 25, 2026

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production

Author Spotlight: Advancing Gene Therapy Research with High-Titer Adeno-Associated Virus Vector Production

Published on: May 3, 2024

Area of Science:

Veterinary Virology
Vaccine Technology
Infectious Disease Research

Background:

Adenoviral (AdV) vectors, including human (HAdV) and chimpanzee (ChAdV) types, were vital for COVID-19 vaccines.
Preexisting immunity to common HAdV types limits the efficacy of current AdV-based vaccines.
Novel AdV platforms are needed to overcome these limitations in vaccine development.

Purpose of the Study:

To review the development and potential of bovine adenovirus type 3 (BAdV-3) as a next-generation vaccine delivery platform.
To highlight BAdV-3's advantages over existing AdV vectors for infectious disease vaccines.
To assess BAdV-3's applicability for both human and veterinary vaccine design.

Main Methods:

Systematic review of scientific literature on BAdV-3 vector system development.
Analysis of BAdV-3's inherent properties: transduction efficiency, transgene capacity, tissue tropism, and immunogenicity.
Evaluation of BAdV-3's ability to evade pre-existing anti-HAdV immunity.
Assessment of BAdV-3's safety profile and pathogenicity.

Main Results:

BAdV-3 vectors demonstrate high transduction efficiency and large transgene capacity.
BAdV-3 possesses broad tissue tropism and effectively induces innate immunity.
BAdV-3 vectors successfully evade pre-existing humoral and cellular immune responses against HAdV.
BAdV-3 exhibits low pathogenicity, indicating a favorable safety profile for a vaccine platform.

Conclusions:

Bovine adenovirus type 3 (BAdV-3) presents a promising alternative vaccine platform.
Its ability to circumvent pre-existing immunity and inherent safety make it suitable for next-generation vaccines.
BAdV-3 holds potential for developing vaccines against a range of human and veterinary infectious agents.